Want full text access to this journal?
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign UpAnnals of Internal Medicine
• journal#1
Jinoos Yazdany, Alfred H J Kim
No abstract text is available yet for this article.
March 31, 2020: Annals of Internal Medicine
#2
(no author information available yet)
Background: Studies suggest that dihydropyridine calcium-channel blockers may be associated with reduced risk for Parkinson disease (PD). Objective: To assess the effect of isradipine, a dihydropyridine calcium-channel blocker, on the rate of clinical progression of PD. Design: Multicenter, randomized, parallel-group, double-blind, placebo-controlled trial. (ClinicalTrials.gov: NCT02168842). Setting: 57 Parkinson Study Group sites in North America...
March 31, 2020: Annals of Internal Medicine
#3
Biplab K Saha, Aakash Modi, Scott Beegle
No abstract text is available yet for this article.
March 31, 2020: Annals of Internal Medicine
#4
Simone V Benatti
No abstract text is available yet for this article.
March 31, 2020: Annals of Internal Medicine
#5
(no author information available yet)
No abstract text is available yet for this article.
March 31, 2020: Annals of Internal Medicine
#6
John H Choe
No abstract text is available yet for this article.
March 31, 2020: Annals of Internal Medicine
#7
Alex Thomas
No abstract text is available yet for this article.
March 31, 2020: Annals of Internal Medicine
#8
Robert M Centor, Jeanne Marrazzo
No abstract text is available yet for this article.
March 31, 2020: Annals of Internal Medicine
#9
Baijayanta Maiti, Joel S Perlmutter
No abstract text is available yet for this article.
March 31, 2020: Annals of Internal Medicine
#10
Alfred H J Kim, Jeffrey A Sparks, Jean W Liew, Michael S Putman, Francis Berenbaum, Alí Duarte-García, Elizabeth R Graef, Peter Korsten, Sebastian E Sattui, Emily Sirotich, Manuel F Ugarte-Gil, Kate Webb, Rebecca Grainger
No abstract text is available yet for this article.
March 30, 2020: Annals of Internal Medicine
#11
Chen Chen, Guiju Gao, Yanli Xu, Lin Pu, Qi Wang, Liming Wang, Wenling Wang, Yangzi Song, Meiling Chen, Linghang Wang, Fengting Yu, Siyuan Yang, Yunxia Tang, Li Zhao, Huijuan Wang, Yajie Wang, Hui Zeng, Fujie Zhang
No abstract text is available yet for this article.
March 30, 2020: Annals of Internal Medicine
#12
Alexander Kutikov, David S Weinberg, Martin J Edelman, Eric M Horwitz, Robert G Uzzo, Richard I Fisher
No abstract text is available yet for this article.
March 27, 2020: Annals of Internal Medicine
#13
David E Kloecker, Melanie J Davies, Kamlesh Khunti, Francesco Zaccardi
The restricted mean survival time (RMST) has been advocated as an alternative or a supplement to the hazard ratio for reporting the effect of an intervention in a randomized clinical trial. The RMST difference allows quantification of the postponement of an outcome during a specified (restricted) interval and corresponds to the difference between the areas under the 2 survival curves for the intervention and control groups. This article presents examples of the use of the RMST in a research and a clinical context...
March 24, 2020: Annals of Internal Medicine
#14
A Russell Localio, Anne R Meibohm, Eliseo Guallar
No abstract text is available yet for this article.
March 24, 2020: Annals of Internal Medicine
#15
Emanuele Angelucci, Junmin Li, Peter Greenberg, Depei Wu, Ming Hou, Efreen Horacio Montano Figueroa, Maria Guadalupe Rodriguez, Xunwei Dong, Jagannath Ghosh, Miguel Izquierdo, Guillermo Garcia-Manero
Background: Iron chelation therapy (ICT) in patients with lower-risk myelodysplastic syndromes (MDS) has not been evaluated in randomized studies. Objective: To evaluate event-free survival (EFS) and safety of ICT in iron-overloaded patients with low- or intermediate-1-risk MDS. Design: Multicenter, randomized, double-blind, placebo-controlled trial (TELESTO). (ClinicalTrials.gov: NCT00940602). Setting: 60 centers in 16 countries...
March 24, 2020: Annals of Internal Medicine
#16
Mounica Vallurupalli, Jean G MacFadyen, Robert J Glynn, Tom Thuren, Peter Libby, Nancy Berliner, Paul M Ridker
Background: Inflammatory cytokines, such as interleukin (IL)-1β, alter iron homeostasis and erythropoiesis, resulting in anemia, but whether inhibition of IL-1β can reverse these effects is unclear. Objective: To determine whether IL-1β inhibition with canakinumab reduces incident anemia and improves hemoglobin levels among those with prevalent anemia. Design: Exploratory analysis of a randomized controlled trial. (ClinicalTrials.gov: NCT01327846)...
March 24, 2020: Annals of Internal Medicine
#17
Eileen Barrett, Elizabeth Lawrence, Daniel Waldman, Heather Brislen
No abstract text is available yet for this article.
March 24, 2020: Annals of Internal Medicine
#18
Mohamed Taha
No abstract text is available yet for this article.
March 24, 2020: Annals of Internal Medicine
#19
Brigitte Decallonne, Pieter-Jan Martens, Annick Van den Bruel, Christine Vanhole, George J Kahaly
No abstract text is available yet for this article.
March 24, 2020: Annals of Internal Medicine
#20
Charlene Dewey, Susan Hingle, Elizabeth Goelz, Mark Linzer
No abstract text is available yet for this article.
March 20, 2020: Annals of Internal Medicine
Fetching more papers... 
